Conquering Diseases

Study Of An Investigational Drug Combination For Maintaining Control Of Non-Small Cell Lung Cancer


Seeking men and women whose non-small cell lung cancer responded or remained stable to platinum-based chemotherapy and are currently taking pembrolizumab for a study of an investigational drug combination for maintenance therapy.


Participants in this study will be randomly assigned to receive either the investigational drug or placebo (looks like the drug, but contains no medicine). All participants will continue to receive pembrolizumab every 3 weeks.

What we're hoping for

We are studying whether an investigational drug combination is safe and effective compared to treatment with pembrolizumab alone in maintaining control of cancer in people whose non-small cell lung cancer responded to platinum-based chemotherapy.

Additional Information Identifier: NCT04475939

 Principal Investigator

William  Walsh, MD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655